Search results
Results from the WOW.Com Content Network
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). [8] For multiple myeloma, it is a first line treatment, and is given with dexamethasone . [ 8 ]
In December 2005, Celgene received approval from the FDA to market Revlimid for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Focalin XR was later launched by Celgene and Novartis in 2005.
Get answers to your AOL Mail, login, Desktop Gold, AOL app, password and subscription questions. Find the support options to contact customer care by email, chat, or phone number.
Sign in to AOL to access your email, news, entertainment, and more.
Myeloma Canada is the only national non-profit organization uniquely devoted to the Canadian myeloma community. The organization helps myeloma patients and raises awareness about this rare form of cancer. [1] Founded in 2005 by two myeloma patients, Myeloma Canada is a patient-driven, patient-focused, grassroots organization, whose goal is to:
You've Got Mail!® Millions of people around the world use AOL Mail, and there are times you'll have questions about using it or want to learn more about its features. That's why AOL Mail Help is here with articles, FAQs, tutorials, our AOL virtual chat assistant and live agent support options to get your questions answered.
The thalidomide molecule is a synthetic derivative of glutamic acid and consists of a glutarimide ring and a phthaloyl ring (Figure 5). [15] [16] Its IUPAC name is 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione and it has one chiral center [15] After thalidomide's selective inhibition of TNF-α had been reported, a renewed effort was put in thalidomide's clinical development.